Hemogenyx Pharmaceuticals Secures Funding to Advance CAR-T Therapy Trials

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has provided an update.

Hemogenyx Pharmaceuticals has secured £285,000 through the issuance of convertible loan notes to advance its clinical trials for HG-CT-1, a CAR-T cell therapy for acute myeloid leukemia. This financial move, primarily supported by existing shareholders, aims to bolster the company’s financial position and reflects confidence in its strategic direction. The conversion of these notes, alongside the issuance of warrants, is expected to enhance shareholder value and facilitate further funding opportunities, strengthening Hemogenyx’s market position.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc operates in the biotechnology industry, focusing on the development of therapies for blood and immune system disorders. Its primary product is HG-CT-1, a CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia.

YTD Price Performance: -22.10%

Average Trading Volume: 21,792

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £11.37M

For a thorough assessment of HEMO stock, go to TipRanks’ Stock Analysis page.